# Romosozumab Use to Build Skeletal Integrity

> **NCT05058976** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Susan L. Greenspan** · enrollment: 184 (actual)

## Conditions studied

- Osteoporosis
- Osteoporosis, Postmenopausal
- Osteoporosis Fracture

## Interventions

- **DRUG:** Romosozumab
- **DRUG:** Placebo
- **DRUG:** Zoledronic acid
- **DIETARY_SUPPLEMENT:** Calcium and Vitamin D

## Key facts

- **NCT ID:** NCT05058976
- **Lead sponsor:** Susan L. Greenspan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-15
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05058976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05058976, "Romosozumab Use to Build Skeletal Integrity". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05058976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*